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PURPOSE. To determine behavioral and genetic factors associated with incidence and age
of progression to advanced age-related macular degeneration (AMD), geographic atrophy
(GA), and neovascular disease (NV), and to quantify these effects.
METHODS. Longitudinal analyses were conducted among 5421 eyes with nonadvanced
AMD at baseline in 2976 participants in the Age-Related Eye Disease Study (mean age of
68.8 (±5.0), 56.1% female). Progression was confirmed based on two consecutive visits
on the AMD severity scale. Separate analyses for progression and age of progression
were performed. All analyses adjusted for correlation between eyes, demographic and
behavioral covariates, baseline severity scale, and genetic variants.
RESULTS. A higher genetic risk score (GRS) including eight genetic variants was associated
with a higher rate of progression to advanced AMD within each baseline severity scale,
especially for the highest risk intermediate level AMD category, and smoking further
increased this risk. When assessing age when progression to advanced disease occurred,
smoking reduced age of onset by 3.9 years (P < 0.001), and higher body mass index
(BMI) led to earlier onset by 1.7 years (P = 0.003), with similar results for GA and NV.
Genetic variants associated with earlier age of progression were CFH R1201C (4.3 years),
C3 K155Q (2.15 years), and ARMS2/HTRA1 (0.8 years per allele).
CONCLUSIONS. Rare variants in the complement pathway and a common risk allele in
ARMS2/HTRA1, smoking, and higher BMI can lead to as much as 11.5 additional years
of disease and treatment burden. Closer adherence to healthy lifestyles could reduce
years of visual impairment.
Keywords: age-related macular degeneration, age of progression, genetics, lifestyles
Age-related macular degeneration (AMD) has a complexcause and remains a significant public health problem
despite recent advances in treatments.1–3 Many patients with
neovascular macular degeneration (NV) disease have resid-
ual visual impairment after treatment with intravitreal injec-
tions, because of varying degrees of chorioretinal atrophy
and scarring. Therefore new therapies are being evaluated.
The advanced dry form with geographic macular atrophy
(GA) has no known treatment, but many clinical trials are
underway.
AMD confers a significant individual and societal burden
and can lead to loss of independence, increased use of health
care resources, and an adverse impact on quality of life. The
prevalence of AMD is increasing as the proportion of our
elderly population rises, and the number of people with
AMD is expected to be 196 million in 2020, increasing to
288 million in 2040.2 AMD is the leading cause of visual
disability in the developed world and the third globally.4
The estimated direct health care costs of visual impairment
in North America caused by AMD is $98 billion and $255
billion globally.5 The level of reduction in quality of life for
severe AMD is comparable to end-stage prostatic cancer or
a catastrophic stroke.6 Prevention of AMD is therefore a key
public health strategy.
A set of genetic, demographic, and environmental vari-
ables can predict with relatively high likelihood which indi-
viduals will more likely progress to advanced AMD.7 It has
also been shown that individuals with rare genetic variants
are more likely to progress.7–9 However, the age at which
the transition from nonadvanced to advanced AMD occurs
is variable, even among those with the same baseline macu-
lar pathology. The independent effect of individual genetic
variants and behavioral variables on this age of progression,
and quantification of the difference in number of years, have
not been evaluated in a longitudinal study. We analyzed data
from a large, well-defined cohort to assess the impact of
both genetic and lifestyle factors on age when transition to
advanced AMD occurs over time, adjusting for other known
factors related to AMD.
Analyses included some new methodologic considera-
tions. AMD incidence is not a linear function of age; risk
increases nonlinearly after age 70.2,7,10 Thus we used age as
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the time scale in conducting time-to-event analyses. Sever-
ity scales for each eye were analyzed separately to better
adjust for baseline macular status. Also, to enhance accuracy
in determining the endpoints, we defined a progressing eye
on the basis of having a severity scale indicating advanced
disease at two consecutive visits. Also, because the effect of
the association between severity scale and AMD is not linear,
we represented severity scale as a set of indicator variables in
the analyses. Finally, we used stepwise regression to identify
relevant or predictive genotypes in deriving a genetic risk
score on the basis of genotypes related to specific outcomes
in longitudinal analyses.
Clinical trials should consider selection criteria that target
particular disease subgroups for therapeutic approaches,
such as those at higher risk of progression or have earlier
age of progression with longer disease burden. To help
achieve this goal, the aims of these analyses were to (i) apply
new methods for evaluating predictors of developing over-
all advanced AMD, GA, and NV, and (ii) evaluate the impact
of both modifiable and genetic risk factors on age when
progression occurs. Herein, we expand upon our previous
preliminary analyses and results on this topic. 11,12
METHODS
Study Population
The Age-Related Eye Disease Study (AREDS) enrolled a
total of 4757 participants in the United States from 1992
to 1998.13 Among these, 2941 individuals (5421 eyes) with
follow-up and with all covariate and genetic data were
analyzed, and 948 eyes progressed to advanced AMD, 487
eyes progressed to GA, and 495 progressed to NV (some eyes
had both endpoints). The mean follow-up time was 9.3 years
(range 0.5–13 years), with a median of 10 years. The study
adhered to the tenets of the Declaration of Helsinki and was
performed under approved institutional review board proto-
cols.
Definition of Progression to Advanced AMD
Incidence of progression to advanced AMD was based on
the eye specific severity scale in the AREDS database.14 The
scale ranges from 1 to 12, with scale 9 as noncentral GA,
10 as central GA, 11 as NV, and 12 as NV and central GA.
Scales 1 to 8 comprise a range from no AMD to early or inter-
mediate stages on the basis of drusen and retinal pigment
epithelial irregularities. An eye that progressed was defined
as transition from scales 1 to 8 to any GA or evidence
of NV or both (levels ≥9) during follow-up. We required
that two consecutive visits have scales corresponding to the
endpoints GA (9–10,12), NV (11–12), and overall advanced
AMD (9–12), because there were several instances of regres-
sion to scales 1–8 after a single scale 9–12. Supplementary
Figure S1 displays examples of the use of this method for
advanced AMD to confirm the endpoints. For progression
to GA, two consecutive visits with scale 9, 10, or 12 were
needed to confirm the progression, as long as NV was never
confirmed before the progression to GA. For progression to
NV, two consecutive visits with scale 11 or 12 were needed
to confirm progression. If an eye progressed to GA first
before NV, it was still included in the analysis of eyes at risk
for NV.
Demographic, Behavioral, and Genetic Factors
Demographic factors including age, gender, race (white,
non-white), education (high school or below, above high
school), and behavioral factors including smoking (never,
past, current) and body mass index (BMI) (<25, 25–<30,
30+) were determined from questionnaires administered at
baseline visits. All analyses were adjusted for the AREDS
treatment assignments including placebo, antioxidants, zinc,
and antioxidants plus zinc. Genotyping was performed using
array-based genotyping and gene sequencing platforms as
previously described.8,9,15–17
Analyses of Progression to Overall Advanced
AMD, GA, and NV
Given that the risk of progression is not necessarily a linear
function of baseline severity scale and this scale is likely to
be the strongest predictor of progression, we represented
the severity scale as a set of indicator variables from 2 to 8
with scale =1 as a reference category. Similarly, because the
risk of AMD is a nonlinear function of age and increases
sharply after age 70, we used age as the time scale in
conducting survival analysis. Thus all the risk sets used in
survival analyses are based on age in one-year intervals,
which was updated throughout the follow-up period. This
eliminates all residual confounding by age in subsequent
analyses. We conducted survival analysis with the eye as the
unit of analysis, using the Cox proportional hazards model,
with the counting process style of input using age as the
time metric. The age interval (age 1, age 2) was determined
for each person, where age1 = baseline age and age2 =
minimum (age at the last follow-up visit, age of progres-
sion). For each risk factor, we calculated a hazard ratio (HR)
that is the ratio of incidence rates at any given point in time
between two subjects that differ by one unit on a specific risk
factor, holding all other risk factors constant. We included
nongenetic variables (sex, race, education, smoking, BMI,
baseline severity scale, and AREDS treatment group) and
then used stepwise selection to identify additional signif-
icant genetic predictors of progression.7 The criteria for
selection were P < 0.05 for both entering and staying in
the model. Finally, we tested for departures or violations of
proportional hazard assumptions by including cross product
terms of follow-up time by smoking and BMI, respectively,
in our risk models.
Genetic Risk Score. The Genetic Risk Score
(GRSAdvancedAMD) was calculated using the variants asso-
ciated with progression to overall advanced AMD (Table 1).
Based on this model, we calculated a GRS = sum of β i,
multiplied by gi , where gi = number of risk alleles present





The GRS was then grouped into tertiles, the severity
scale was categorized into four groups (1–5/6/7/8) and a
second Cox model was run using age as the time metric
included GRS tertile and severity scale category and in addi-
tion controlling for sex, education, race, BMI, smoking, and
AREDS treatment group. We used the baseline statement of
SAS with the second survival model to estimate the survival
curve for a subject with average value for all covariates.
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TABLE 1. Genetic Variants Associated With Progression to Overall Advanced AMD, GA, and NV
Advanced AMD
(948/5421 Eyes) GA (487/5421 Eyes) NV (495/5421 Eyes)
Genetic Variants HR (95% CI)* P Value HR (95% CI)* P Value HR (95% CI)* P Value
Complement pathway
CFH Y402H: rs1061170 1.31 (1.13–1.51) <0.001
CFH: rs1410996 1.34 (1.18–1.52) <0.001 1.34 (1.11–1.61) 0.003
CFH R1210C: rs121913059 2.94 (1.78–4.85) <0.001 2.48 (1.06–5.82) 0.037 2.82 (1.56–5.11) <0.001
C3 R102G: rs2230199 1.16 (1.04–1.30) 0.007 1.18 (1.01–1.38) 0.033
C3 K155Q: rs147859257 2.01 (1.45–2.77) <0.001 2.29 (1.56–3.35) <0.001
Angiogenesis pathway
TGFBR1: rs334353 0.84 (0.71–1.00) 0.044
Immune/inflammatory pathway
ARMS2/HTRA1: rs10490924 1.44 (1.30–1.59) <0.001 1.24 (1.08–1.43) 0.002 1.65 (1.42–1.91) <0.001
TNFRSF10A: rs13278062 0.88 (0.77–1.01) 0.066
Extracellular matrix
COL8A1: rs13095226 1.19 (1.02–1.38) 0.023 1.28 (1.03–1.59) 0.028
DNA repair/protein binding
RAD51B: rs8017304 0.82 (0.73–0.91) <0.001 0.76 (0.65–0.89) <0.001
HSPH1/B3GALTL: rs9542236 1.12 (1.02–1.24) 0.019 1.16 (1.01–1.34) 0.038
* HRs were calculated for time to progression using age as the time scale with the eye as the unit of analysis, adjusted for sex, race,
education, smoking, BMI, AMD baseline eye-specific severity scale, and AREDS treatment.
In the third step of the analysis, we used the baseline
survival curve to estimate the five-year survival probabil-
ity (S) with specific combinations of severity scale and GRS
tertile, and average levels of all other covariates:




j=2 γ j SEVj
)
where GRSi and SEVj for the ith GRS and jth severity scale
category, respectively.
We then estimated the five-year incidence, I(5) = 1-
S(5), for each combination of GRS category and severity
scale category. Similar GRSs were also constructed for GA
(GRSGA) and NV (GRSNV). Similar plots were constructed
for different GRS tertiles within combinations of smoking
status (current/past/never) and representative severity scales
(2/5/8), for 12 years.
Area Under the Curve (AUC). We calculated a risk
score for each eye of each subject and used the Mann-
Whitney-U statistic to estimate the AUC, the probability that
a random progressing eye will have a higher risk score than
a random nonprogressing eye, after controlling for age.18
For this purpose, we compared risk scores of eyes that
progressed within five years (progressing eyes) to risk scores
of eyes that were followed up for at least five years and did
not progress (nonprogressing eyes).
Age of Progression. Among eyes that progressed,
multivariate analysis was performed to calculate the effect
of behavioral covariates and each genetic variant on age of
progression to advanced AMD using mixed effects regres-
sion models. Thus a subject may contribute either one or
two observations to the dataset according to the number of
eyes that progressed during the study. A similar stepwise
procedure was used forcing in nongenetic variables to iden-
tify genetic variables associated with age of progression. The
genetic variables were combined into an overall genetic risk
score (GRSage) that reflect the associations of several vari-
ants with age of progression. For variables associated with
earlier age of progression, histograms of the distribution of
age of progression were calculated. In addition, boxplots of
age of progression for combinations of smoking and BMI
were obtained. All analyses were calculated using SAS 9.4.
Two-sided P values were calculated, and 0.05 was used as
the level of significance.
Population Attributable Fraction. We computed
the percentage of eyes from people with specific
behavioral characteristics (Pj), for example, smoking
(current/past/never) and BMI (<25/25–29/30+) where j =
1,…9 corresponds to combinations of smoking and BMI
categories, and the hazard ratio (HRj) corresponding to each
combination of characteristics versus the reference group
(e.g., never smoker and BMI < 25). We then computed the







A similar calculation was performed to assess the percent-
age of progression prevented if eyes from people with GRS
tertiles 2 and 3 were in GRS tertile 1. The GRS calcula-
tion was adjusted for specific combinations of severity scale
and age and other demographic characteristics (e.g., sex,
race) and behavioral characteristics (e.g., smoking and BMI)
assuming proportional hazards for each characteristic and
no interactions among combinations of characteristics. The
smoking and BMI attributable fraction calculations were




Baseline characteristics of the study population are shown
in Supplementary Table S1. Among 5421 eyes, 948 (17.5%)
progressed to advanced AMD over 12 years (mean follow-
up time 9.6 years ± SD 2.4 years), 487 (9%) progressed to
GA and 495 (9%) progressed to NV. Eighty-one percent of
the people were 65 or older at baseline, 44% were male,
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TABLE 2. GRS for Progression to Advanced AMD, GA, and NV
Advanced AMD
(948/5421 Eyes) GA (487/5421 Eyes) NV (495/5421 Eyes)
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
GRS tertile
1 1 REF 1 REF 1 REF
2 1.95 (1.48–2.57) <0.001 1.39 (0.97–1.99) 0.075 1.82 (1.24–2.66) 0.002
3 3.03 (2.31–3.97) <0.001 1.90 (1.35–2.68) <0.001 3.68 (2.58–5.25) <0.001
GRS* 2.67 (2.22–3.21) <0.001 2.72 (2.00–3.69) <0.001 2.72 (2.21–3.34) <0.001
GRS 90th vs. 10th percentile† 2.97 (1.21–7.27) 2.18 (1.36–3.50) 3.64 (1.03–12.78)
* Per 1 unit increase in Genetic Risk Score (GRSAdvancedAMD). GRS for each outcome was derived based on the genes identified in Table 1.
GRS was adjusted for sex, race, education, smoking, BMI, AMD baseline eye-specific severity scale, and AREDS treatment, where updated
age was the time scale and the eye was the unit of analysis.
† The difference between the 10th and 90th percentile for GRS was 1.09 for overall AMD, 0.78 for GA, and 1.29 for NV.
For the GRS of progression to advanced AMD, the means are −0.21 (±0.216); 0.29 (±0.125); 0.88 (±0.282) for first, second, and third
tertile respectively, and 0.65 (±0.420) for the overall GRS. The range are −0.40 – 0.46; 0.47 – 0.83; 0.83 – 2.29 for first, second, and third
tertile respectively.
For the GRS of progression to GA, the means are 0.22 (±0.124); 0.55 (±0.060); 0.91 (±0.208) for first, second, and third tertile respectively,
and 0.56 (±0.310) for the overall GRS.
For the GRS of progression to NV, the means are −0.21 (±0.216); 0.30 (±0.125); 0.88 (±0.282) for first, second, and third tertile respectively,
and 0.32 (±0.497) for the overall.
96% were white, and 66% had at least some education
beyond high school. About 6% were current smokers, 47%
were past smokers, whereas more than two thirds of the
population were overweight. Fifty-six percent were very
low risk for progression at baseline (scales 1–2), 23%
were low to moderate risk (scales 3–5), whereas 20% had
intermediate- to high-risk AMD (scales 6–8). A total of
31 genes were considered, of which 10 genes were in
the complement pathway, two were in the angiogenesis
pathway, five were in the lipid pathway, six were in the
immune/inflammatory pathway, five were in extracellular
matrix, and three were in the DNA repair/protein binding
pathway.
Genetic and Modifiable Determinants of Incident
Age-Related Macular Degeneration
Table 1 displays the genetic variants associated with progres-
sion to incident advanced AMD, GA, and NV. Eight genetic
variants were associated with progression to advanced AMD,
after adjusting for demographic and behavioral factors,
AMD baseline eye-specific severity scale and AREDS treat-
ment category. The genetic variants represented several
biologic pathways: complement, immune, inflammatory,
lipid, extracellular matrix, DNA repair and protein bind-
ing. For advanced AMD, four of the variants were in the
complement pathway with hazard ratios ranging from 1.16
(C3 R102G) to 2.94 (CFH R1210C) per risk allele. In addi-
tion, there was one gene in the immune pathway, one in
extracellular matrix, and two in DNA repair pathway (hazard
ratio ranging from 0.82 (RAD51B) to 1.44 (ARMS2/HTRA1),
related to progression. Five genes were associated with
progression to GA, whereas eight were related to progres-
sion to NV. For NV, two additional variants in the angio-
genesis and immune pathway were associated only with
progression to NV. The effects of each of the genetic vari-
ants can be visualized in a forest plot in Supplementary
Figure S2.
A full risk model with the estimates of each variant and
the nongenetic factors are presented in Supplementary Table
S2. White subjects showed a borderline significant higher
rate of progression to overall AMD and GA compared with
nonwhites. Current history of smoking increased the risk for
progression to all three outcomes, and past smoking history
increased the risk of NV.Higher BMI increased the likelihood
of progression to overall AMD and NV, but it was borderline
significant for GA. The severity scale was strongly associ-
ated with progression to all three outcomes, particularly for
progression to GA.
Finally for the outcome advanced AMD, we tested for
violations of proportional hazard assumptions with smok-
ing and BMI and found no significant effect modification of
either variable when stratified by time in the study either
when represented as categorical variables or as ordinal vari-
ables (represented as 1/2/3).
Genetic Risk Score and AUC Analyses for
Progression to Advanced Age-Related Macular
Degeneration
Table 2 displays the GRS for progression to each outcome
derived from the selected genetic variants in Table 1. These
scores were significantly associated with all three outcomes,
adjusting for all covariates including the baseline sever-
ity scale (P value <0.001 for all outcomes). For advanced
AMD overall, the highest tertile of GRS was associated with
a threefold increase in rate of progression compared to
the lowest tertile, and almost a threefold increased risk of
progression between the ninetieth versus tenth percentile.
For GA, the risks were somewhat less pronounced between
highest and lowest tertiles than for overall advanced AMD
(HR of 1.90), with more than a twofold higher rate of
progression for the ninetieth versus tenth percentile. For
NV, the risk was 3.7-fold higher for the third GRS tertile
compared to the first tertile, and similarly was 3.6 fold higher
for ninetieth versus tenth percentile.
Figure 1 displays Kaplan-Meier (KM) survival curves
for progression according to GRS tertiles, adjusting for all
covariates, using the baseline command of PROC PHREG
of SAS. The estimated 12-year risk of progression was 12%,
20%, and 25% for tertiles 1, 2, 3; indicating about a twofold
increased risk for GRS tertile 3 versus 1.
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FIGURE 1. Survival curves for probability of not progressing to advanced age-related macular degeneration according to GRS tertiles.
Figure 2 displays KM curves for GRS tertiles stratified
by severity scales and smoking status. There is little differ-
ence in survival according to GRS for severity scale of
2 (early signs of AMD) and a small proportion of subjects
progressed by 12 years. Conversely, there were large differ-
ences in survival by GRS categories for severity scale
5 and especially for scale 8, which were magnified further
among individuals who were current smokers. For exam-
ple, among past smokers with baseline severity scale of 8,
the 12-year survival probability was 45% for GRS 1 versus
10% for GRS 3. For the current smokers with a severity
scale of 8, the 12-year survival probability was 20% for
GRS 1 versus less than 5% for GRS 3. Similar findings
were apparent for severity scale 5. In summary, GRS differ-
ences in survival were only apparent for subjects with at
least intermediate AMD, and most discriminating among
subjects with the later preadvanced stages of intermediate
disease.
Figure 3 displays the 5 year and 12 year cumulative inci-
dence of progression to advanced AMD, GA, and NV, for vari-
ous combinations of baseline severity scale and GRS, which
adjust for competing mortality risks. For overall progression,
there was a strong effect of severity scale on incidence of
AMD. Within specific levels of the baseline severity scale,
there was an additional gradient of risk when subdividing
by tertiles of GRS, particularly in severity scale range 6–8. For
example, for severity scale 8, there was approximately a 50%
cumulative incidence of advanced AMD over 12 years if the
GRS was in the lowest tertile compared with 95% cumulative
incidence if the GRS was in the highest tertile. However, if
the severity scale was in the lower range 1 to 5, there was a
low probability of progression at five or 12 years, regardless
of the GRS.
Subjects in the highest tertile of GRS and the higher sever-
ity scales (6–8) had an increased risk for progression to GA
when mutually adjusting for GRS and AMD baseline scale.
The incidence rates for progression to NV in eyes with base-
line scales 6 to 8 were similar, although within each of these
baseline grades, similar to GA, the third tertile of GRS had
the highest risk of progression, followed by tertile 2, and
the lowest risk was seen in the lowest GRS for each baseline
scale 6, 7, and 8.
As shown in Table 3, the AUC for the five-year incidence
of advanced AMD was 0.88 among the group with baseline
severity scale 1 to 8, adjusting for only demographic and
behavioral factors, and was 0.89 after adding the GRS, indi-
cating that there is only a small increase in discrimination
when adding the GRS (P = 0.032). Because this AUC calcu-
lation is dominated by the large number of eyes in severity
scale range 1 to 5, a group with low risk of progression,
we also restricted the analysis to eyes within baseline scales
6–8. The AUC was lower but was substantially improved by
including tertiles of GRS in addition to the severity scale
for overall AMD (AUC = 0.039, P < 0.001). This is illus-
trated by at least a threefold difference in incidence rate of
progression comparing GRS tertile 3 to tertile 1 for individu-
als within severity scale 6 to 8 (Fig. 3). The effect of the GRS
was also more pronounced when restricting eyes to higher
risk baseline severity scales 6 to 8 for progression to NV
( = 0.062, P < 0.001). In addition, for NV there appears to
be a threshold effect of severity scale with a large difference
in risk of progression between severity scales 1 to 5 versus
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FIGURE 2. Survival curves for probability of not progressing to advanced AMD over time stratified by GRS tertiles, smoking status, and AMD
severity scale.
6 to 8, but little change in risk among severity scales 6 to
8. Overall, these results indicate that the GRS provides addi-
tional differential information, particularly for eyes at high
risk of progression (with baseline scales 6–8).
Age of Progression to Advanced AMD
Table 4 displays the multivariate analysis of the effects of
demographic, behavioral, ocular, and genetic factors on age
of progression to advanced AMD, GA, and NV. The average
age among progressors is shown for a reference group with
none of the risk factors: female, nonwhite, higher education,
never smoker, normal BMI, baseline severity scale 1, and
none of the genetic risk variants.
Subjects who were current smokers (P < 0.001) or had
higher BMI ≥30 (P = 0.003) had an earlier age at progres-
sion to advanced AMD relative to the average age ( 3.9 years
and 1.7 years, respectively), compared with the reference
categories of never smoking or having a BMI < 25. Simi-
larly for GA, current smoking and higher BMI were associ-
ated with earlier age of progression (3.5 years and 2 years,
respectively). Smoking was associated with 3.24 years earlier
progression to NV.
Baseline severity scale 8 compared to scale 1 was asso-
ciated with earlier age of progression to AMD (average of
3.2 years earlier age of progression; P = 0.007). There was a
similar trend for GA (average of 4.4 years earlier, P = 0.073).
A significant trend for earlier age of progression for increas-
ing severity scale was seen for both advanced AMD and GA.
Three variants were found to be associated with age of
progression to advanced AMD: CFH R1210C: rs121913059
with an average of 4.3 years earlier age at progression
among carriers of this mutation compared with non-carriers
(P = 0.026), C3 K155Q: rs147859257 with an average of
2.15 years earlier age at progression for carriers (P = 0.027),
and ARMS2/HTRA1 A69S rs10490924 with an average of 0.79
years earlier age of progression per risk allele (P = 0.006).
For carriers of the homozygous genotype for ARMS2/HTRA1,
with two risk alleles, the impact would be an average of 1.58
(2 × 0.79) years earlier age of progression. For GA, only CFH
R1210C was associated with earlier age of progression (aver-
age of 5.4 years earlier among carriers, P = 0.033). For NV,
only ARMS2 was found to be associated with earlier age of
progression (average of 0.93 years per risk allele, P = 0.018).
Figure 4 shows the distribution of age of progression
to advanced AMD among progressors according to various
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FIGURE 3. 5 year and 12 year cumulative incidence for progression to advanced AMD, GA, and NV, according to the GRS and baseline AMD
severity scale.
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TABLE 3. AUC for Progression to Advanced AMD, GA, and NV Over Five Years According to Baseline Severity Scale, With and Without
Genetic Variables
















Outcome AUC (SE) AUC (SE) AUC AUC (SE) AUC (SE) AUC
Advanced AMD 0.880 (0.008) 0.890 (0.008) 0.010 (0.005);
P = 0.032
0.617 (0.018) 0.656 (0.018) 0.039 (0.012);
P < 0.001
GA 0.928 (0.009) 0.929 (0.009) 0.002 (0.005);
P = 0.70
0.720 (0.021) 0.729 (0.021) 0.009 (0.012);
P = 0.41
NV 0.820 (0.014) 0.840 (0.013) 0.0179 (0.008);
P = 0.023
0.529 (0.024) 0.593 (0.023) 0.062 (0.016);
P < 0.001
Models 1 and 3 adjusted for age, sex, race, education, smoking, BMI, AMD baseline eye-specific severity scale, and AREDS treatment.
Models 2 and 4 adjusted for the same variables as Models 1 and 3, plus genetic variables which were specific for each outcome.
Models 1 and 2 consider the entire range of baseline severity scales 1–8, while models 3 and 4 only consider baseline severity scales
of 6–8.
AUC, difference in AUC (model 2 vs. 1 and model 4 vs. 3). Each of the AUC estimates were adjusted for updated age in five-year age
groups (≤64 ; 65–<70 ; 70–<75 ; 75–<80; 80+) with weights according to the inverse variance of the age specific AUC. The weighting varies
between each of the individual model specific AUC estimates as well as the AUC difference between competing models. In general, strata
with larger number of events get more weight.
TABLE 4. Multivariate Analysis of Associations Between Demographic, Behavioral, Ocular, and Genetic Factors and Age of Progression to
Advanced AMD, GA, and NV Among Eyes that Progressed
Advanced AMD (948 Eyes) GA (487 Eyes) NV (495 Eyes)
Variables ESTIMATES (±SE)* P Value ESTIMATES (±SE)* P Value ESTIMATES (±SE)* P Value
Average age† 81.12 (±2.44) <0.001 80.25 (±6.28) <0.001 79.25 (±2.75) <0.001
Demographic
Male 0.77 (±0.44) 0.084 0.11 (±0.64) 0.86 0.87 (±0.59) 0.14
White 0.04 (±2.14) 0.98 −1.66 (±5.81) 0.77 0.16 (±2.37) 0.95
>High school −0.36 (±0.42) 0.40 −0.36 (±0.62) 0.56 −0.28 (±0.57) 0.62
Behavioral
Current smoker −3.90 (±0.74) <0.001 −3.49 (±1.17) 0.003 −3.24 (±0.97) <0.001
Past smoker −0.74 (±0.46) 0.10 −0.38 (±0.64) 0.56 −0.37 (±0.61) 0.55
BMI 25–29 −0.92 (±0.5) 0.069 −1.11 (±0.7) 0.12 −0.15 (±0.68) 0.83
BMI ≥30 −1.66 (±0.55) 0.003 −2.06 (±0.79) 0.009 −1.17 (±0.74) 0.11
Baseline Severity Scale
1 REF REF REF
2 −0.87 (±1.42) 0.54 0.67 (±2.57) 0.80 −1.88 (±1.84) 0.31
3 −0.75 (±1.39) 0.59 −1.66 (±2.2) 0.45 0.26 (±1.75) 0.88
4 −0.67 (±1.15) 0.56 −1.45 (±2.48) 0.56 0.11 (±1.42) 0.94
5 −0.61 (±1.16) 0.60 −1.44 (±2.39) 0.55 0.82 (±1.41) 0.56
6 −0.40 (±1.13) 0.73 −1.31 (±2.38) 0.58 0.38 (±1.35) 0.78
7 −2.01 (±1.12) 0.076 −2.98 (±2.37) 0.21 −0.90 (±1.35) 0.51
8 −3.17 (±1.16) 0.007 −4.36 (±2.39) 0.073 −0.37 (±1.45) 0.80
P_trend <0.001 <0.001 0.55
Genetic variants
Complement pathway
CFH R1210C: rs121913059 −4.33 (±1.94) 0.026 −5.40 (±2.52) 0.033




−0.79 (±0.29) 0.006 −0.93 (±0.39) 0.018
* β estimates for age of progression among eyes which progressed in a multivariate model where all nongenetic variables were included
in a starting model and stepwise selection was used to identify additional significant genetic variables. All analyses were based on the eye
as the unit of analysis using PROC MIXED of SAS.
† The average age among progressors for a reference group with none of the risk factors: sex (female), race (non-white), education
(higher than high school), smoking (never smoker), BMI (<25), AMD baseline severity scale (scale 1), AREDS treatment (placebo), and none
of the risk variants.
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FIGURE 4. Distribution of age of progression to advanced age-related macular degeneration among progressors according to (A)
ARMS2/HTRA1, (B) CFH R1210C, (C) C3 K155Q, (D) smoking status, (E) smoking status and ARMS2/HTRA1 alleles, and (F) smoking
status and BMI.
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TABLE 5. Association Between GRS Incorporating CFH R1210C, C3 K155Q, and ARMS2, and Age of Progression to Overall Advanced AMD
Group N* β Estimates (±SE)† P Value Range of GRS
Having no risk allele 266 0 REF 0
Only 1 risk allele in one of the genes 451 −0.25 (±0.49) 0.61 >0 and <0.755
Having 2 or more risk alleles for any of the
3 genes; or, 1 risk allele for 2 or 3 genes
244 −1.88 (±0.56) <0.001 0.755 and above
GRS‡ −2.45 (±0.65) <0.001 0.00–1.44
* Number of eyes with known genetic variants for GRSage.
† β estimates for age of progression among eyes that progressed. One unit of the β estimate refers to one year of age. The average age
among progressors for a reference group with none of the risk factors was 80.9 years (±1.3): female, non-white, higher education, never
smoker, normal BMI, baseline severity scale 1, and having no risk alleles.
‡ The GRSage was derived based on the genes associated with age of progression to overall AMD shown in Table 4. The effect of GRS
was adjusted for sex, race, education, smoking, BMI, AMD baseline eye-specific severity scale, and AREDS treatment. For example, there is
an estimated 2.45 years earlier age of progression per unit increase in GRS.
TABLE 6A. Population Attributable Fraction for Behavioral Factors
BMI and










Never 47.9 <25 Never <25 1.0 11.6
25-29 Never <25 1.17
≥30 Never <25 1.33
Past 46.5 <25 Past <25 1.0 12.5
25-29 Past <25 1.17
≥30 Past <25 1.33
Current† 5.6 <25 Past <25 2.27 60.6
25-29 Past <25 2.65
≥30 Past <25 3.01
Total 14.7
* Percent of disease progression prevented—computed from percent of eyes within the group, and the HR of changing from the specific
exposure within the group to the optimal exposure in the reference (REF) group.
† Considers the change from current to past smoker, and BMI ≥25 to <25.
genetic and non-genetic subgroups. Figures 4A to 4C display
the mean age of progression shifted toward younger ages for
the common ARMS2/HTRA1 risk allele and the rare CFH and
C3 variants. In the homozygous ARMS2/HTRA1 risk group,
approximately 45% of eyes progressed at age <75, compared
with 30% for the homozygous nonrisk group. In addition, for
the rare variant CFH R1210C, approximately 65% of carriers
vs 30% of non-carriers had age of progression <75. A simi-
lar but weaker trend was seen for carriers vs non-carriers
of the C3 K155Q variant. Approximately 50% of current
smokers vs 30% of never smokers had an age of progres-
sion <75. Similar trends were seen when considering combi-
nations of risk factors (see Figures 4E, 4F). Approximately
50% to 55% of subjects who were current smokers and also
homozygous ARMS2 carriers had age of progression <75,
compared with 30% of never smokers and ARMS2 nonrisk
genotype. Combinations of current smoking and high BMI
showed a similar trend of earlier age of progression. Supple-
mentary Figure S3 shows the box plots of the median and
distribution of age of progression among subjects grouped
by smoking status and BMI status, with the category of
current smokers plus highest BMI showing the earliest age of
progression.
Table 5 displays the association between GRSage and age
of progression to advanced AMD incorporating three genes
related to this outcome. Age of progression was reduced by
approximately 1.9 years among subjects with two or more
risk alleles; furthermore, age of progression was reduced by
2.5 years per one unit increase in GRS.
Tables 6A and 6B show population-attributable risks for
modifiable behavioral and genetic factors. For never and past
smokers, the percentage of progression to advanced AMD
prevented by optimizing their BMI to <25 was 11.6% and
12.5%, respectively. Conversely, for current smokers, opti-
mizing their behavior (i.e., changing to past smoker and
BMI to <25) would prevent approximately 60% of progres-
sion to advanced AMD. Over for the entire study population,
14.7% of disease could be prevented by optimizing modi-
fiable behaviors. Similarly, approximately 37% of disease
progression would be prevented if GRS profile changed from
TABLE 6B. Population Attributable Fraction for GRS Factors*
Tertile % of Eyes HR Percent Prevented†
1 33.3 1.0 37.3
2 33.4 1.87
3 33.3 2.90
* GRS was a composite of 8 genetic variants associated with the
progression to advanced age-related macular degeneration, going
from tertile 2 or 3, to 1.
† Percent of disease progression prevented—computed from
percent of eyes within the group.
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We determined that behavioral factors modify risk of
progression to advanced AMD, GA, and NV, and genetic
variation at multiple AMD risk alleles is associated with
increased rate of progression after adjusting for baseline
severity scale and all covariates. In other words, for each
level of baseline severity scale, especially for the higher risk
scales 6–8, time to conversion to late AMD decreased with
increasing genetic risk and with unhealthy behaviors.
Age when progression to advanced AMD occurred was
also affected by genes and environment. Smoking and
higher BMI were associated with earlier age of progres-
sion and thus more years of disease and treatment burden.
Genetic susceptibility also played a role, and higher genetic
burden due to carrying high risk rare variants in CFH or
C3 in the complement pathway, or the common risk allele
in the ARMS2/HTRA1 gene, were associated with earlier
age of transitioning from non-advanced to advanced AMD.
Smoking together with a higher BMI were associated with
5.6 years earlier age of progression to advanced disease,
and genetic burden determined by a common variant, e.g.
ARMS2/HTRA1, was associated with lower age of progres-
sion by 1.6 years for homozygous carriers (combined total
of up to 7.2 years). If an additional rare variant, such as CFH
R1210C, was present, then disease onset would be shortened
by an additional 4.3 years, or as much as 11.5 years in total
earlier onset of advanced disease and longer disease burden,
adjusting for all other covariates.
The greatest impact of genetic factors on enhancing prog-
nostic ability to predict who will progress to advanced
AMD, especially for NV, was seen among eyes with baseline
scales 6–8, which represent increasing levels of intermediate
disease with larger drusen. This is important because these
are the eyes at highest risk for developing advanced stages
causing visual loss. It appears therefore that there are three
distinct subgroups: eyes with severity scale 1–5 with low
risk regardless of their genetic burden, eyes with interme-
diate risk, which have severity scales 6–8 but a low genetic
burden, and another group of eyes with high risk, which
have severity scales of 6 to 8 and a high genetic burden.
For eyes with severity scales 6 to 8 and high genetic burden
(highest tertile of GRS), about 35% will progress to advanced
AMD over five years, whereas about 10% of eyes with base-
line scales 6 to 8 with low genetic risk (lowest tertile of GRS)
and <5% of eyes with baseline scales of 1 to 5 developed
advanced AMD over 5 years.
Proposed Mechanisms
The behavioral lifestyle factors found to play a role in
disease progression and earlier age of being affected with
advanced stages are associated with biologic mechanisms
that could heighten risk. Cigarette smoking is associated
with increased oxidative stress, lipid peroxidation, platelet
aggregation and increased fibrinogen levels.19 Nicotine has
been reported to increase size and severity of experimen-
tal choroidal neovascularization and may increase VEGF
levels.20 Smoking, abdominal and overall obesity are associ-
ated with higher levels of inflammatory cytokines, including
high sensitivity C-reactive protein.21–23
The complement pathway is a major player in the patho-
genesis of AMD, and the rare CFH R1210C variant has the
strongest effect on AMD among those who carry this vari-
ant compared to common and other variants.9 The rare C3
variant also confers higher impact than the common vari-
ants.17 These rare variants in the complement pathway cause
dysregulation and overactivation of the complement path-
way. The ARMS2/HTRA1 variant has a lower effect size but
is much more common in the population, and therefore
also has an important impact.24,25 Proposed mechanisms
involve inflammation and complement activation, mitochon-
dria, effects on photoreceptors, and VEGF expression.26
Comparison with Literature
Previous studies explored behavioral and genetic factors
related to progression of disease using different methodolo-
gies than what we used in these analyses.1,7,8,10,27 The liter-
ature regarding age of progression is more sparse. A Euro-
pean cross-sectional study evaluated only the neovascular
form of AMD in a cohort of 275 subjects in Europe, among
which 214 had complete information. They found that smok-
ing history, CFH Y402H and the A69S variant in ARMS2 were
associated with the earlier age of diagnosis of neovascular
AMD, based on a retrospective review of medical records.28
We have previously shown that carriers of the rare variant
CFH R1210C tend to have younger age of onset of AMD in
a case-control study9 and have higher risk of progression.8
The study reported herein differs in several ways. Most
notably, this was a longitudinal analysis of age of transi-
tion to advanced AMD as well as GA and NV in a large
cohort, and both rare and common genetic variants, as
well as behavioral factors were considered in the analyses.
We adjusted the statistical model to account for correlation
between fellow eyes and all covariates in the same model,
to determine which variables were independently related.
As noted earlier, we also adjusted fully for age and required
confirmed endpoints at two consecutive visits based on a
detailed severity scale to reduce misclassification.
Strengths and Limitations
Strengths of the study include the new analyses summa-
rized above, the standardized data collection, and longitu-
dinal follow-up with exams and imaging at regular inter-
vals. Grades were assigned without knowledge of genetic
and nongenetic predictive factors. Limitations include the
use of baseline data as predictors of subsequent progres-
sion, although many studies have reliably assessed baseline
data and associations with subsequent outcomes. Further-
more, predictive models rely on baseline data to predict risk
of disease in later years in an elderly population. Fundus
photography was used to determine the severity scale and
time of progression to advanced AMD, and use of optical
coherence tomography or machine learning methods could
improve precision of these outcomes.29
CONCLUSIONS
In summary, in this first longitudinal analysis of the impact
of both genetic and non-genetic factors on age of progres-
sion to GA and NV, results underscore the impact of nature
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and nurture on both developing advanced disease leading
to visual loss, and also increasing the likelihood of having
this adverse outcome at an earlier age. A combined risk of
smoking, higher BMI and genetic factors could lower age
of developing advanced stages of AMD by 7 to 11.5 years,
leading to a longer burden of disease and more treatments.
Thus, adhering to healthy habits and changing unhealthy
habits could reduce societal and economic costs.
Knowledge of factors underlying age of transition to
advanced AMD can impact clinical care by underscoring
the importance of adhering to healthy habits and provides
biologic mechanisms to explore to shorten disease burden.
Accounting for individual differences in lifestyles, as well
as genetic susceptibility, may lead to avenues for personal-
ized medicine. We will ultimately be able to target different
disease subgroups in clinical trials and offer more precise
therapeutic approaches.
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